Serum levels of CXCL2 and CXCL5 exhibited race-specific differences, while CCL23 showed both race- and cancer-specific differences supporting the potential contribution of systemic chemokines in differential outcomes among races in association with prostate cancer. The gene discussed is CXCL2; the disease is prostate carcinoma.